Tonghua Dongbao Pharmaceutical Co.Ltd(600867) 4 issue the annual report of 2021 on the evening of April 18. During the reporting period, the company achieved a revenue of 3.268 billion yuan, a year-on-year increase of 12.99%; The net profit attributable to shareholders of listed companies was 1.308 billion yuan, a year-on-year increase of 40.69%. In 2021, the company plans to distribute a cash dividend of 3 yuan (including tax) for every 10 shares, with a total cash dividend of about 600 million yuan. It is worth mentioning that over the past 10 years, Tonghua Dongbao Pharmaceutical Co.Ltd(600867) accumulated dividends have exceeded 3 billion yuan.
In 2021, Tonghua Dongbao Pharmaceutical Co.Ltd(600867) two-way expand the channel scope, further cultivate the grass-roots level, and improve the coverage and depth of county-level and grass-roots hospitals; With the opportunity of the listing of glargine and insulin aspartate, actively expand the sales channels of class III hospitals and improve the market share in urban central hospitals.
During the reporting period, the sales of insulin products of the company achieved rapid growth, especially the sales of insulin analogues increased by more than 200% year-on-year, of which insulin glargine is still in the rapid and large-scale stage. So far, it has covered more than 3800 secondary and above hospitals in China; Insulin aspart, which was approved to be listed in October 2021, has been promoted at full speed in all provinces, and has begun to contribute sales revenue; In addition, the income of human insulin products continued to grow steadily and the market share was further expanded. Benefiting from the large-scale effect brought by the increase in the proportion of high gross profit products and scale growth, the company’s profitability continued to rise.
Tonghua Dongbao Pharmaceutical Co.Ltd(600867) continue to strengthen R & D and innovation, improve independent R & D capacity, revitalize stock assets, improve asset use efficiency, and concentrate on the development and transformation to innovative pharmaceutical enterprises. The annual R & D investment reached 380 million yuan, a year-on-year increase of 56.37%. The company actively distributes cutting-edge targets and therapies, expands the coverage of indications and broadens the field of disease treatment. Based on more unmet clinical needs, the indications of multiple products from diabetes to cover weight loss and non-alcoholic fatty liver disease (NASH) and other diseases have been expanded. The product therapy field has been extended to other areas of Endocrinology and metabolism, such as gout / hyperuricemia.
During the reporting period, there were 3 new drugs in the field of diabetes treatment, 2 new drugs for gout / hyperuricemia. Among them, the clinical application of SGLT1 / SGLT2 / DPP4 three target inhibitor has been approved, and the first subject in clinical phase I has been enrolled. The clinical application of URAT1 inhibitor (thdbh130 / 131) has been approved. It is expected that the first subject in clinical phase I will be enrolled in the near future. So far, the company has submitted dozens of international and Chinese patent applications for class I innovative drugs.
At the same time, the company has ploughed the field of diabetes treatment, enriching and optimizing the product structure, improving research and development efficiency, accelerating the development of pipeline, and achieving substantial results in research and development. During the reporting period, the company’s insulin aspart injection, sitagliptin phosphate tablets and sitagliptin metformin tablets were approved for listing; The application for production of insulin aspart 30 and 50 injections, repaglinide tablets and engliejing tablets was accepted; The application for parallel phase III and phase I clinical trials of insulin lispro injection was approved; Soluble glargine lispro double insulin injection (currently the only compound preparation that can successfully combine long-acting glargine insulin and quick acting lispro insulin) was applied for clinical application. It was approved by China food and Drug Administration and German Federal Drug and medical device administration in March and April 2022 respectively.
With regard to the key work in 2022, Tonghua Dongbao Pharmaceutical Co.Ltd(600867) said that in terms of R & D, it will continue to invest in innovative R & D, accelerate the process of R & D pipeline and accelerate the transformation to innovative pharmaceutical enterprises; Adhere to the development strategy of “independent R & D + foreign cooperation”, continuously improve the efficiency of innovative R & D and the level of corporate governance internally, strictly select high-quality cooperation units and projects externally, carry out extensive exchanges with universities, medical institutions and scientific research institutes on production, learning, research and medical activities, and take multiple measures to comprehensively improve the core competitiveness of the company.
In terms of commercialization, on the one hand, the company will accelerate the access speed and sales growth of insulin analogues nationwide by taking advantage of the implementation and landing opportunity of winning the bid for national centralized purchase of insulin products; On the other hand, increase the investment in retail channels, private hospitals and other external markets, expand the incremental market with the company’s high-quality product quality and after-sales service, continuous market development and brand influence accumulated over the years, and further improve the company’s product sales and market share.
